Is acetyl octapeptide-3 FDA-approved, and what does the research show?

What is acetyl octapeptide-3?

Acetyl octapeptide-3 is a synthetic peptide, a chain of eight amino acids made in a laboratory ¹,². Its maker, Lipotec ², sells it through Lubrizol as SNAP-8, a solution of the peptide in water for use in cosmetic formulas ⁹. The chain is acetyl hexapeptide-8, the older ingredient sold as Argireline, with two amino acids added ¹,²,³. Both peptides mimic one end of SNAP-25, a nerve-ending protein that helps release acetylcholine, the chemical messenger that tells a muscle to contract ¹⁰,². The maker aims it at expression wrinkles, the folds that repeated frowning or squinting leaves in the skin ⁹.

Is acetyl octapeptide-3 FDA-approved?

No. FDA approves no cosmetic ingredient before it goes on sale, except color additives ⁴. FDA's page on its authority over cosmetics, current as of November 18, 2025, says that "cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives" ⁴. Acetyl octapeptide-3 is not FDA-approved as a drug either: Drugs@FDA lists no approved acetyl octapeptide-3 product as of November 9, 2026 ⁵. It is a cosmetic ingredient sold for creams and serums ¹.

The companies that make or sell a cosmetic "have a legal responsibility to ensure the safety of their products," and the law requires no specific tests ⁴. Since the Modernization of Cosmetics Regulation Act of 2022, where FDA finds a "reasonable probability that a cosmetic is adulterated or misbranded" and that its use "will cause serious adverse health consequences or death," it "has the authority to order a mandatory recall if the responsible person refuses to do so voluntarily" ¹¹.

A product counts as a cosmetic or a drug according to what it is intended for ¹². Intent can be shown by the claims made for it, how consumers see it, or an ingredient with a well-known therapeutic use ¹². An article "intended to affect the structure or any function of the body" is a drug ¹². FDA's page on anti-aging products, current as of February 25, 2022, draws the line at wrinkles ¹³.

A product intended "to remove wrinkles or increase the skin's production of collagen" is "a drug or a medical device" ¹³. One intended "to make lines and wrinkles less noticeable, simply by moisturizing the skin" is a cosmetic ¹³. The same page says FDA "is concerned about drug claims made for products marketed as cosmetics, such as skin care products with anti-wrinkle or anti-aging claims that involve supposed effects on the structure or function of the skin" ¹³. So FDA has not looked at the safety or effectiveness of a serum carrying this peptide before it is sold ⁴.

See the FDA status of every peptide, updated weekly.

How does acetyl octapeptide-3 work?

The proposed mechanism is the one claimed for acetyl hexapeptide-8 ²,³. Reviews describe the peptide competing with SNAP-25 for a place in the SNARE complex, the protein assembly through which acetylcholine release happens ². With less acetylcholine the muscles behind frown and squint lines would contract less, so the lines they leave would soften ². The maker calls its product "a premium topical alternative to Botulinum Toxin injections" ⁹.

For a cream or a patch, that remains a hypothesis. A 2026 review of cosmetic peptides writes that the parent peptide's mechanism "does not establish penetration to the human neuromuscular target after routine topical application" ³. The same review treats acetyl octapeptide-3 as a related commercial concept, "not as clinically interchangeable" with acetyl hexapeptide-8 ³. No published study of acetyl octapeptide-3 reaching muscle through intact human skin was found in PubMed or PubMed Central, the National Library of Medicine's databases, on November 10, 2026.

What does the research show?

Studied in people, only in blends. One patch study, in Korea, enrolled 24 people aged 30 to 65 with eye wrinkles ¹. Each wore the active patch at one eye and a placebo patch, one with no active ingredient, at the other ¹. The placebo was hyaluronic acid alone, a water-holding molecule the skin makes ¹. They wore the patches nightly for 14 days and then every third day to day 28 ¹.

The active patch was 90 percent hyaluronic acid and 5 percent of a vitamin C derivative ¹. It also held 4 percent of a lipid the authors say raises hyaluronic acid synthesis, and 0.03 percent acetyl octapeptide-3 ¹. Twenty-one people finished; measured skin roughness fell on the treated side, and all five roughness measures differed from the placebo side at day 28 ¹.

The authors suggest the peptide explains the change seen after one application and the other two ingredients the later changes, but the study tested only the blend ¹. It does not describe randomization or blinding, and it was supported by Raphas, a company four of the five authors were affiliated with ¹. The second patch study, a 12-week study run at one site, loaded hyaluronic acid microneedle patches with five ingredients, acetyl octapeptide-3 among them ⁶. Healthy people with aged skin wore them beside the eyes and on the forearm ⁶. It reports fine lines 25.8 percent lower and skin hydration 15.4 percent higher, and names no control group ⁶.]

Two other published studies tested face serums that hold acetyl octapeptide-3 with other ingredients ⁷,⁸. In the larger, 50 women aged 35 to 65 used a serum twice daily for 24 weeks, and 47 finished ⁷. In the other, 33 women aged 35 to 55 were enrolled and 31 finished 12 weeks of twice-daily use ⁸. Both judged each woman's skin against its own starting state, and neither names a placebo group ⁷,⁸. Both serums were PCA Skin products, and Colgate-Palmolive funded both studies, the second together with PCA Skin ⁷,⁸.

Acetyl hexapeptide-8, the parent peptide, has a randomized, placebo-controlled trial of 60 people that lasted four weeks ¹⁰. In that design people are assigned by chance to the peptide or to a placebo, so the two groups can be compared ¹⁰. No trial of that design, and no human study of acetyl octapeptide-3 on its own, was found in PubMed or PubMed Central on November 10, 2026. No published study comparing the two peptides in people was found there on the same date.

The maker's page reports "up to 72% reduction in maximum depth of wrinkle"; that figure is the company's, and no published study carrying it was found ⁹. The longest of the four human studies ran 24 weeks ⁷.

What are the side effects?

In the 28-day Korean patch study, clinicians saw no redness, swelling or scaling at the application site at any visit ¹. None of the 21 who finished reported itching, stinging, burning, tightness or prickling, and the authors add that a larger study is needed to confirm skin safety ¹. In the 12-week patch study, "none of the subjects reported any primary or cumulative skin reactions" ⁶. Both findings belong to a patch holding several ingredients, worn by healthy adults, so they say little about the peptide alone or about a cream.

No independent safety review of the ingredient was found as of November 10, 2026. The usual reviewer for such ingredients is the Cosmetic Ingredient Review, a panel paid for by the cosmetics industry's trade association, which describes the panel's reviews as independent ¹⁴. Its Quick Reference Table of December 2025 lists no finding for acetyl octapeptide-3, and its 2026 priority list does not name it ¹⁵,¹⁶.

The same table records the panel's conclusion on the parent peptide ¹⁵. The panel found the ingredient, entered in the table as "Acetyl Hexapeptide-8 Amide," safe in cosmetics "when the concentration does not exceed 0.005%," with the data "insufficient" to judge safety above that ¹⁵. No published data on long-term toxicity were found on November 10, 2026.

In sport

Acetyl octapeptide-3 is not named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency, under that name or as SNAP-8 ¹⁷.

What JumpstartMD offers

JumpstartMD does not prescribe acetyl octapeptide-3. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.